Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Payables (2018 - 2025)

Dna X (SONM) has disclosed Payables for 8 consecutive years, with $25.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Payables rose 178.54% year-over-year to $25.2 million, compared with a TTM value of $25.2 million through Sep 2025, up 178.54%, and an annual FY2024 reading of $22.8 million, up 15.12% over the prior year.
  • Payables was $25.2 million for Q3 2025 at Dna X, up from $23.5 million in the prior quarter.
  • Across five years, Payables topped out at $25.2 million in Q3 2025 and bottomed at $8.1 million in Q2 2022.
  • Average Payables over 5 years is $16.2 million, with a median of $16.3 million recorded in 2021.
  • The sharpest move saw Payables tumbled 61.06% in 2024, then surged 178.54% in 2025.
  • Year by year, Payables stood at $9.5 million in 2021, then surged by 123.01% to $21.1 million in 2022, then decreased by 6.05% to $19.8 million in 2023, then rose by 15.12% to $22.8 million in 2024, then increased by 10.4% to $25.2 million in 2025.
  • Business Quant data shows Payables for SONM at $25.2 million in Q3 2025, $23.5 million in Q2 2025, and $19.6 million in Q1 2025.